H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Raises Target Price to $11
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Raises Target Price to $10
Nuvation Bio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $7 Price Target
Buy Rating on Nuvation Bio: Promising Taletrectinib Results and Strong Valuation Support $7 Target
Nuvation Bio Is Maintained at Outperform by RBC Capital
Nuvation Bio Analyst Ratings
TD Cowen Maintains Nuvation Bio(NUVB.US) With Buy Rating
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Raises Target Price to $6
TD Cowen Maintains Nuvation Bio(NUVB.US) With Buy Rating
TD Cowen Sticks to Its Buy Rating for Nuvation Bio (NUVB)
Nuvation Bio Analyst Ratings
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $5 Price Target
Jefferies Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $10
Jefferies Releases a Buy Rating on Nuvation Bio (NUVB)
Nuvation Bio Is Maintained at Buy by HC Wainwright & Co.
Nuvation Bio Analyst Ratings
H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Cuts Target Price to $7
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $5 Price Target
Wedbush Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $5